INVO Fertility 2025 Q3 Earnings Strong Revenue Growth Despite Widening Net Loss

INVO Fertility (IVF) reported fiscal 2025 Q3 earnings on November 17, 2025, delivering a 22.6% year-over-year revenue increase but widening net losses. The results beat revenue expectations but fell short of profitability improvements. Management reiterated acquisition plans and operational efficiency goals, with no formal guidance adjustments provided.

Revenue

Clinic revenue led the growth with $1.72 million, while product sales contributed an additional $34,871. Total revenue reached $1.76 million, reflecting a 22.6% year-over-year increase driven by expanded clinic operations and INVOcell device adoption.

Earnings/Net Income

Despite a 94.9% improvement in EPS (from -$15.11 to -$0.77), the net loss widened by 62.2% to $2.64 million, underscoring persistent financial challenges.

Post-Earnings Price Action Review

The stock’s historical post-earnings volatility, including an 18.2% surge in November 2024, suggests potential short-term gains following revenue beats. However, delayed filings and sector headwinds could dampen market confidence. A direct backtest of the strategy remains unavailable due to limited historical data.

CEO Commentary

CEO Steve Shum highlighted 18% organic clinic growth, 130% INVOcell revenue growth, and a robust acquisition pipeline. He emphasized policy-driven market expansion and operational efficiency as key drivers for future profitability.

Guidance

The company expects to complete at least one acquisition in the coming months, with continued focus on INVOcell revenue growth and operational efficiencies. Management remains optimistic about policy shifts expanding IVF access.

Additional News

1. Delayed 10-Q Filing: INVO Fertility delayed its Q3 2025 10-Q filing, raising concerns about operational transparency.

2. Acquisition Pipeline: The CEO confirmed plans to acquire at least one clinic soon, citing a growing pipeline of targets.

3. Policy Momentum: Recent federal updates enabling employer-sponsored infertility benefits are expected to boost industry growth and patient access.

Financial Highlights

• Revenue: $1.76M (+22.6% YoY)

• Net Loss: $2.64M (+62.2% YoY)

• INVOcell Revenue: 130% YoY growth

• Acquisition Plans: At least one expected in 2025 Q4

Key Risks

• Persistent net losses and cash flow constraints

• Regulatory delays and operational transparency concerns

• Sector-specific market volatility impacting stock performance

Investor Takeaway

While revenue growth and strategic expansion are promising, investors must weigh ongoing losses and operational risks. The acquisition pipeline and policy tailwinds offer long-term potential, but near-term profitability remains uncertain.